Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020. This was partly necessitated by the acute need to advance COVID-19 therapeutics and diagnostics as quickly as possible, requiring large amounts of capital and shared expertise. The other driving factor was the buoyancy of capital markets, as investors actively sought drug- and device-maker opportunities, previously thought of as defensive holdings.

Leave a Reply

Your email address will not be published. Required fields are marked *